Because basic science and clinical investigations are expensive endeavors, philanthropic support is essential if this program is to move forward. Berdon Lawrence, a business and community leader in Houston, took the personal initiative to launch a fund-raising effort by donating $2 million of his own funds. He also helped Baylor College of Medicine and MD Anderson Cancer Center raise a total of $10 million over the next three years, to ensure the successful start-up of The Rolanette and Berdon Lawrence Bone Disease Program of Texas.
You can help by contributing to this fund-raising effort. Innovative research findings supported by philanthropic gifts enhance our ability to secure funding from the National Institutes of Health, the American Cancer Society and other national peer-review agencies.
Donate Online -- You may name the type of research or program you wish to support when you make a donation on MD Anderson's secure credit card donation form. Or visit Baylor College of Medicine's online contributions page.
The Impact of Your Support
Philanthropic support for The Rolanette and Berdon Lawrence Bone Disease Program of Texas will enable us to:
- Establish a sequencing laboratory at Baylor College of Medicine to search for mutations in genes affecting bone formation.
- Expand the histologic laboratory for analysis of bone from animal models at Baylor and establish a similar core for human samples at MD Anderson.
- Develop a competitive start-up grant program that will award grants to the most promising
projects, enabling investigators to collect the preliminary data needed to compete successfully for federal support.
- Establish a monthly seminar series and an annual research and clinical retreat to share information on research conducted by members of the program.
- Develop a curriculum for teaching medical students bone biology and the latest advances in the clinical management of bone-related disorders, an educational area that is underdeveloped.
- Create a tissue bank for the storage and study of bone samples to foster our progress in understanding the causes of bone disease at the molecular level.